Specific regulation of T helper cell 1-mediated murine colitis by CEACAM1. 2004

Hideki Iijima, and Markus F Neurath, and Takashi Nagaishi, and Jonathan N Glickman, and Edward E Nieuwenhuis, and Atsushi Nakajima, and Daohong Chen, and Ivan J Fuss, and Nalan Utku, and Daniel N Lewicki, and Christoph Becker, and Thomas M Gallagher, and Kathryn V Holmes, and Richard S Blumberg
Gastroenterology Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.

Carcinoembryonic antigen-related cellular adhesion molecule 1 (CEACAM1) is a cell surface molecule that has been proposed to negatively regulate T cell function. We have shown that CEACAM1 is associated with specific regulation of T helper cell (Th)1 pathways, T-bet-mediated Th1 cytokine signaling, and Th1-mediated immunopathology in vivo. Mice treated with anti-mouse CEACAM1-specific monoclonal antibody (mAb) CC1 during the effector phase exhibited a reduced severity of trinitrobenzene sulfonic acid colitis in association with decreased interferon (IFN)-gamma production. Although oxazolone colitis has been reported as Th2 mediated, mice treated with the CC1 mAb or a CEACAM1-Fc chimeric protein exhibited a reduced severity of colitis in association with a significant reduction of IFN-gamma and T-bet activation, whereas signal transducer and activator of antigen 4 activation was unaffected. Both interleukin-4 and IFN-gamma gene-deficient mice exhibited less severe colitis induction by oxazolone. Direct ligation of T cells in vitro with the murine hepatitis virus spike protein, a natural ligand for the N-domain of CEACAM1, inhibited the differentiation of naive cells into Th1 but not Th2 cells and activation of Th1 but not Th2 cytokine production. These results indicate that CEACAM1 isoforms are a novel class of activation-induced cell surface molecules on T cells that function in the specific regulation of Th1-mediated inflammation such as that associated with inflammatory bowel disease.

UI MeSH Term Description Entries
D007141 Immunoglobulin Fc Fragments Crystallizable fragments composed of the carboxy-terminal halves of both IMMUNOGLOBULIN HEAVY CHAINS linked to each other by disulfide bonds. Fc fragments contain the carboxy-terminal parts of the heavy chain constant regions that are responsible for the effector functions of an immunoglobulin (COMPLEMENT fixation, binding to the cell membrane via FC RECEPTORS, and placental transport). This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN. Fc Fragment,Fc Fragments,Fc Immunoglobulin,Fc Immunoglobulins,Ig Fc Fragments,Immunoglobulin Fc Fragment,Immunoglobulins, Fc,Immunoglobulins, Fc Fragment,Fc Fragment Immunoglobulins,Fc Fragment, Immunoglobulin,Fc Fragments, Ig,Fc Fragments, Immunoglobulin,Fragment Immunoglobulins, Fc,Fragment, Fc,Fragments, Ig Fc,Immunoglobulin, Fc
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D010081 Oxazolone Immunologic adjuvant and sensitizing agent. 2-Phenyl-4-(ethoxymethylene)oxazol-5-one,4-Ethoxymethylene-2-phenyloxazolone,4 Ethoxymethylene 2 phenyloxazolone
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D003092 Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER. Colitides

Related Publications

Hideki Iijima, and Markus F Neurath, and Takashi Nagaishi, and Jonathan N Glickman, and Edward E Nieuwenhuis, and Atsushi Nakajima, and Daohong Chen, and Ivan J Fuss, and Nalan Utku, and Daniel N Lewicki, and Christoph Becker, and Thomas M Gallagher, and Kathryn V Holmes, and Richard S Blumberg
November 2006, Current opinion in gastroenterology,
Hideki Iijima, and Markus F Neurath, and Takashi Nagaishi, and Jonathan N Glickman, and Edward E Nieuwenhuis, and Atsushi Nakajima, and Daohong Chen, and Ivan J Fuss, and Nalan Utku, and Daniel N Lewicki, and Christoph Becker, and Thomas M Gallagher, and Kathryn V Holmes, and Richard S Blumberg
July 1997, Journal of immunology (Baltimore, Md. : 1950),
Hideki Iijima, and Markus F Neurath, and Takashi Nagaishi, and Jonathan N Glickman, and Edward E Nieuwenhuis, and Atsushi Nakajima, and Daohong Chen, and Ivan J Fuss, and Nalan Utku, and Daniel N Lewicki, and Christoph Becker, and Thomas M Gallagher, and Kathryn V Holmes, and Richard S Blumberg
October 1994, Journal of immunology (Baltimore, Md. : 1950),
Hideki Iijima, and Markus F Neurath, and Takashi Nagaishi, and Jonathan N Glickman, and Edward E Nieuwenhuis, and Atsushi Nakajima, and Daohong Chen, and Ivan J Fuss, and Nalan Utku, and Daniel N Lewicki, and Christoph Becker, and Thomas M Gallagher, and Kathryn V Holmes, and Richard S Blumberg
February 2005, The Journal of experimental medicine,
Hideki Iijima, and Markus F Neurath, and Takashi Nagaishi, and Jonathan N Glickman, and Edward E Nieuwenhuis, and Atsushi Nakajima, and Daohong Chen, and Ivan J Fuss, and Nalan Utku, and Daniel N Lewicki, and Christoph Becker, and Thomas M Gallagher, and Kathryn V Holmes, and Richard S Blumberg
January 2002, The Journal of experimental medicine,
Hideki Iijima, and Markus F Neurath, and Takashi Nagaishi, and Jonathan N Glickman, and Edward E Nieuwenhuis, and Atsushi Nakajima, and Daohong Chen, and Ivan J Fuss, and Nalan Utku, and Daniel N Lewicki, and Christoph Becker, and Thomas M Gallagher, and Kathryn V Holmes, and Richard S Blumberg
January 2008, The Journal of biological chemistry,
Hideki Iijima, and Markus F Neurath, and Takashi Nagaishi, and Jonathan N Glickman, and Edward E Nieuwenhuis, and Atsushi Nakajima, and Daohong Chen, and Ivan J Fuss, and Nalan Utku, and Daniel N Lewicki, and Christoph Becker, and Thomas M Gallagher, and Kathryn V Holmes, and Richard S Blumberg
January 1995, Ciba Foundation symposium,
Hideki Iijima, and Markus F Neurath, and Takashi Nagaishi, and Jonathan N Glickman, and Edward E Nieuwenhuis, and Atsushi Nakajima, and Daohong Chen, and Ivan J Fuss, and Nalan Utku, and Daniel N Lewicki, and Christoph Becker, and Thomas M Gallagher, and Kathryn V Holmes, and Richard S Blumberg
August 1994, Proceedings of the National Academy of Sciences of the United States of America,
Hideki Iijima, and Markus F Neurath, and Takashi Nagaishi, and Jonathan N Glickman, and Edward E Nieuwenhuis, and Atsushi Nakajima, and Daohong Chen, and Ivan J Fuss, and Nalan Utku, and Daniel N Lewicki, and Christoph Becker, and Thomas M Gallagher, and Kathryn V Holmes, and Richard S Blumberg
December 2015, Experimental biology and medicine (Maywood, N.J.),
Hideki Iijima, and Markus F Neurath, and Takashi Nagaishi, and Jonathan N Glickman, and Edward E Nieuwenhuis, and Atsushi Nakajima, and Daohong Chen, and Ivan J Fuss, and Nalan Utku, and Daniel N Lewicki, and Christoph Becker, and Thomas M Gallagher, and Kathryn V Holmes, and Richard S Blumberg
June 2005, European journal of immunology,
Copied contents to your clipboard!